Clinical trials
Phase 3 Cardiomyopathies trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2007 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Recruiting | 5 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alnylam Pharmaceuticals | 5 |
| Scios, Inc. | 5 |
| Eidos Therapeutics, a BridgeBio company | 3 |
| Pfizer | 2 |
| Ventracor | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Corewell Health East | 1 |
| Fundación Cardioinfantil Instituto de Cardiología | 1 |
| I.M. Sechenov First Moscow State Medical University | 1 |
| Intellia Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiomyopathies | 38 |
| Heart Failure | 14 |
| Amyloidosis | 10 |
| Renal Insufficiency | 6 |
| Heart Diseases | 5 |
| Alzheimer Disease | 4 |
| Amyloid Neuropathies, Familial | 4 |
| Amyloidosis, Familial | 4 |
| Myocarditis | 3 |
| Cardiomyopathy, Dilated | 2 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.